Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
South African Press Association - September 11, 2007
The TAC also welcomed the Health Department's announcement at Monday's meeting of the South African National Aids Council that dual therapy as a minimum treatment for preventing mother-to-child HIV transmission was due for "imminent approval".
According to Tshabalala-Msimang, a 2001 Constitutional Court judgement limited her department to implementing only monotherapy nevirapine to HIV-positive pregnant mothers.
Beeld reported the minister as saying at Monday's meeting that were it not for the TAC's 2001 court case, pregnant mothers would already have had access to dual-therapy treatment. She also claimed that nevirapine monotherapy did not work.
"This is a gross distortion of the truth," said the TAC in a statement.
"The decision to use single-dose nevirapine as opposed to AZT or other more effective regimens was taken by the Department of Health when it initiated 18 PMTCT [preventing mother-to-child transmission] pilot sites before the case.
"But it refused to extend the programme beyond these pilot sites. Single-dose nevirapine was the cheapest regimen available and this probably informed the state's decision."
At one stage during Monday's meeting, the TAC's Mark Heywood sat shaking his head while Tshabalala-Msimang spoke about the ineffectiveness of nevirapine in preventing mother-to-child transmission, reported Beeld.
According to the TAC's statement, a number of public health facilities were ready to roll out PMTCT but were prevented from doing so by the Health Department, giving rise to the TAC's court case.
Currently only the Western Cape was implementing dual-therapy treatment. This had reduced the mother-to-child HIV infection rate to about 8%, said the TAC.
In a speech in the National Assembly in 1999, Tshabalala-Msimang quoted from a study during which 308 women took AZT and 310 nevirapine. The latter was found to be "markedly more effective", safer, less expensive and more practical than AZT or any other drug tested so far, in preventing mother-to-child transmission, she said.
Nevirapine was also considerably cheaper that ATZ, at R30 per mother and child as opposed to R400.
070911
SA070903
Copyright © 2007 - South African Press Association. Reproduction of this article (other than one copy for personal reference) must be cleared through the South African Press Association, Cotswold House, Greenacres Office Park, Cnr. Victory & Rustenburg Roads, VICTORY PARK, PO BOX 7766, JOHANNESBURG, 2000; Fax No: +27 11 782-1587/8, Tel No: +27 11 782-1600.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .